Clinical phenotypes and outcomes associated with SARS-CoV-2 Omicron variant JN.1 in critically ill COVID-19 patients: a prospective, multicenter cohort study

medRxiv - Intensive Care and Critical Care Medicine Pub Date : 2024-03-13 DOI:10.1101/2024.03.11.24304075

Nicolas de Prost, Etienne Audureau, Antoine Guillon, Lynda Handala, Sebastien Preau, Aurelie Guigon, Fabrice Uhel, Quentin Le Hingrat, Flora Delamaire, Claire Grolhier, Fabienne Tamion, Alice Moisan, Cedric Darreau, Jean Thomin, Damien Contou, Amandine Henry, Thomas Daix, Sebastien Hantz, Clement Saccheri, Valerie Giordanengo, Tai Pham, Amal Chaghouri, Pierre Bay, JeanMichel Pawlotsky, Slim Fourati

{"title":"Clinical phenotypes and outcomes associated with SARS-CoV-2 Omicron variant JN.1 in critically ill COVID-19 patients: a prospective, multicenter cohort study","authors":"Nicolas de Prost, Etienne Audureau, Antoine Guillon, Lynda Handala, Sebastien Preau, Aurelie Guigon, Fabrice Uhel, Quentin Le Hingrat, Flora Delamaire, Claire Grolhier, Fabienne Tamion, Alice Moisan, Cedric Darreau, Jean Thomin, Damien Contou, Amandine Henry, Thomas Daix, Sebastien Hantz, Clement Saccheri, Valerie Giordanengo, Tai Pham, Amal Chaghouri, Pierre Bay, JeanMichel Pawlotsky, Slim Fourati","doi":"10.1101/2024.03.11.24304075","DOIUrl":null,"url":null,"abstract":"A notable increase in severe cases of COVID-19, with significant hospitalizations due to the emergence and spread of JN.1 was observed worldwide in late 2023 and early 2024. During the study period (November 2022-January 2024), 56 JN.1- and 126 XBB-infected patients were prospectively enrolled in 40 French intensive care units. JN.1-infected patients were more likely to be obese (35.7% vs 20.8%; p=0.033) and less frequently immunosuppressed than others (20.4% vs 41.4%; p=0.010). JN.1-infected patients required invasive mechanical ventilation support in 29.1%, 87.5% of them received dexamethasone, 14.5% tocilizumab and none received monoclonal antibodies. Day-28 mortality of JN.1-infected patients was 14.6%.","PeriodicalId":501249,"journal":{"name":"medRxiv - Intensive Care and Critical Care Medicine","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"medRxiv - Intensive Care and Critical Care Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1101/2024.03.11.24304075","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

A notable increase in severe cases of COVID-19, with significant hospitalizations due to the emergence and spread of JN.1 was observed worldwide in late 2023 and early 2024. During the study period (November 2022-January 2024), 56 JN.1- and 126 XBB-infected patients were prospectively enrolled in 40 French intensive care units. JN.1-infected patients were more likely to be obese (35.7% vs 20.8%; p=0.033) and less frequently immunosuppressed than others (20.4% vs 41.4%; p=0.010). JN.1-infected patients required invasive mechanical ventilation support in 29.1%, 87.5% of them received dexamethasone, 14.5% tocilizumab and none received monoclonal antibodies. Day-28 mortality of JN.1-infected patients was 14.6%.

查看原文本刊更多论文

COVID-19 重症患者中与 SARS-CoV-2 Omicron 变体 JN.1 相关的临床表型和预后：一项前瞻性多中心队列研究

2023年底至2024年初，全球范围内观察到COVID-19重症病例明显增加，JN.1的出现和传播导致大量患者住院治疗。在研究期间（2022 年 11 月至 2024 年 1 月），法国 40 家重症监护病房前瞻性地招募了 56 名 JN.1 感染者和 126 名 XBB 感染者。与其他患者相比，JN.1感染者更容易肥胖（35.7% 对 20.8%；P=0.033），免疫抑制的发生率也更低（20.4% 对 41.4%；P=0.010）。29.1%的JN.1感染患者需要有创机械通气支持，87.5%的患者接受地塞米松治疗，14.5%接受托西珠单抗治疗，没有患者接受单克隆抗体治疗。JN.1感染患者第28天的死亡率为14.6%。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

medRxiv - Intensive Care and Critical Care Medicine

自引率

0.00%

发文量